Mode
Text Size
Log in / Sign up

Spatial patterns of glioblastoma progression following upfront chemoradiation and salvage therapyAnalysis shows where glioblastoma tumors typically grow after treatment

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that most glioblastoma progressions occur within the local field, which may influence salvage therapy planning.

This meta-analysis examined the spatial distribution of tumor progression in patients with glioblastoma who received upfront chemoradiation and temozolomide followed by salvage therapy. The study specifically looked at whether progression occurred locally within the treatment field, at the margins, or in distant areas outside the initial radiation field.

The results showed that a majority of first progressions after upfront treatment were located within the local field. Following salvage therapy, while most progressions remained local, a notable proportion exhibited broad escape patterns or non-enhancing progression. These findings suggest that tumor behavior varies significantly following different stages of intervention.

The authors noted several limitations, including significant heterogeneity between studies and inconsistent definitions of spatial boundaries. Additionally, data regarding non-enhancing progression was limited by sparse reporting in the original source studies. Because this analysis is based on observational data, the results indicate associations rather than direct causality.

Clinically, these patterns may assist in determining patient eligibility for focal salvage interventions. However, the high degree of heterogeneity suggests that these findings should be interpreted with caution when making individual treatment decisions.

Living with a glioblastoma diagnosis is incredibly difficult. For patients and their families, every piece of information about how the tumor behaves matters. One major question for doctors is where exactly the cancer will reappear after initial treatments like chemotherapy and radiation. Understanding these patterns helps medical teams decide on the best ways to treat the cancer when it begins to grow again.

To get a clearer picture, researchers looked at data from over 10,500 patients across 107 different studies. They wanted to see where the tumor progressed in relation to the area that was first treated with radiation and chemotherapy. This type of analysis helps identify whether the cancer stays in one spot or spreads far away from the original site.

The results showed a clear pattern. In the majority of cases, about 79% of patients saw their tumors grow in the local area where they were first treated. A much smaller number of people, about 17%, saw the cancer spread to distant areas outside the original treatment zone. When doctors looked at what happened after salvage therapy (treatment given after the initial plan failed), about 60% of cases still showed growth in the local area, while about 39% showed a broad escape pattern where the cancer spread more widely.

It is important to keep these findings in perspective. While the data shows clear trends, there were several limitations in the study. The different studies used different ways to define what counts as "local" or "distant," and there was a lot of variation between the different reports. Additionally, some types of growth are harder to track accurately because they do not show up clearly on standard scans.

For patients right now, this means that while these patterns help doctors plan for future treatments, every case is unique. This study does not change immediate treatment plans today, but it highlights the need for more consistent ways to report how tumors grow. It helps researchers and doctors better understand the typical path of the disease so they can improve how they manage it over time.

What this means for you:
Most glioblastoma tumors grow near the initial treatment site, which helps doctors plan for future care.

Study Details

Study typeMeta analysis
Sample sizen = 10,529
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
PURPOSE: Spatial patterns of glioblastoma (GBM) progression inform focal salvage eligibility, but interpretation across studies is limited by heterogeneous spatial definitions, high between-study heterogeneity, and incomplete reporting of non-enhancing/FLAIR-dominant progression. We synthesized reported progression-location involvement after upfront radiotherapy/temozolomide (RT/TMZ) and salvage therapy. METHODS: We systematically searched PubMed and Scopus from January 1, 2000, to February 1, 2026, and performed arm-level random-effects meta-analysis of logit-transformed proportions. Enhancing progression was harmonized as non-mutually exclusive local/in-field, marginal/field-edge, and distant/out-of-field involvement among evaluable cases, using each study's spatial framework. The supplementary broad escape-pattern construct was defined as reported progression beyond purely local/in-field enhancing failure. RESULTS: We included 107 studies (122 arms; 10,529 patients). At first progression after upfront RT/TMZ ± TTF, reported local/in-field enhancing involvement among evaluable cases was 79.2% (95% CI 75.7-82.3; k = 94; n = 6,989; I²=84.8%), and distant/out-of-field involvement was 16.9% (95% CI 14.3-19.9; k = 89; n = 6,493; I²=85.2%). After salvage therapy, local/in-field involvement remained the majority pattern reported among evaluable cases (59.8%, 95% CI 52.8-66.4; k = 27; n = 1,572; I²=80.5%), with distant/out-of-field involvement of 17.5% (95% CI 12.9-23.3; k = 21; n = 1,307; I²=75.5%) and a supplementary broad escape-pattern estimate of 38.6% (95% CI 31.9-45.9; k = 27; n = 1,572; I²=80.1%). Non-enhancing/FLAIR-dominant progression was sparsely and likely selectively reported; only six recurrent/salvage arms contributed data, yielding an exploratory pooled estimate of 27.8% (95% CI 12.8-50.3; n = 216; I²=75.7%). CONCLUSION: Published GBM cohorts show predominantly local/in-field enhancing progression after upfront therapy (~ 80%) and persistent majority local/in-field involvement after salvage therapy (~ 60%). Standardized reporting of enhancing, non-enhancing/FLAIR-dominant, disseminated, posterior fossa, and brainstem progression is needed.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.